In the present study, we have found a novel role of celastrol as an anti-tumor medicine through reducing the expression of BGN to activate RIP1/RIP3/MLKL signaling pathway, leading to necroptosis and decreased secretion of pro-inflammatory cytokines in HGC-27 and AGS cells (Figure 7). Here, RIPK3 is linked to neoplasm.